Logo image of NTLA

INTELLIA THERAPEUTICS INC (NTLA) Stock News

NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD

9.46  +0.26 (+2.83%)

Premarket: 9.23 -0.23 (-2.43%)

NTLA Latest News, Press Relases and Analysis

News Image
2 days ago - Zacks Investment Research

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

Mentions: ILMN BEAM QURE CRSP ...

News Image
4 days ago - Zacks Investment Research

ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent

Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.

Mentions: HALO ACAD

News Image
5 days ago - Intellia Therapeutics, Inc.

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in...

News Image
7 days ago - Zacks Investment Research

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.

Mentions: NVS INCY HALO

News Image
8 days ago - Yahoo Finance

Cava: Rapid Growth but Some Concerns

Fast-casual restaurant company Cava reported revenue and earnings that handily beat expectations. Same-restaurant sales growth of 10.8% was especially impressive. The company's forecast calls for same-restaurant sales growth to decelerate as the year goes on.

Mentions: CAVA TSHA TTWO AMAT ...

News Image
8 days ago - Zacks Investment Research

Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News Image
14 days ago - Zacks Investment Research

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.

Mentions: REGN BEAM ANIP

News Image
14 days ago - Zacks Investment Research

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.

Mentions: LLY NKTR ANIP

News Image
15 days ago - Zacks Investment Research

Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised

MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.

Mentions: BEAM ANIP MIRM

News Image
15 days ago - Zacks Investment Research

Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.

Mentions: BEAM AMRN ANIP

News Image
15 days ago - Zacks Investment Research

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 12.70% and 14.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: BFRI

News Image
15 days ago - Intellia Therapeutics, Inc.

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the...

News Image
16 days ago - Zacks Investment Research

Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y

PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.

Mentions: PRGO PBYI ELEV

News Image
16 days ago - Zacks Investment Research

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.

Mentions: ANIP ESPR IMCR

News Image
16 days ago - Zacks Investment Research

JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook

Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.

Mentions: JAZZ PBYI ELEV

News Image
16 days ago - Zacks Investment Research

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.

Mentions: BEAM ANIP IMCR

News Image
16 days ago - Zacks Investment Research

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 22.92% and 103.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: CCCC

News Image
17 days ago - Intellia Therapeutics, Inc.

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...

News Image
17 days ago - Zacks Investment Research

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 20% and 8.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: CRMD

News Image
18 days ago - Zacks Investment Research

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mentions: OBIO

News Image
22 days ago - Zacks Investment Research

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mentions: KRYS

News Image
22 days ago - Zacks Investment Research

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

News Image
22 days ago - Intellia Therapeutics, Inc.

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...

News Image
23 days ago - Yahoo Finance

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The popular growth investor keeps adding to some of her favorite stocks.

Mentions: AMD SHOP TSLA

News Image
23 days ago - The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The popular growth investor keeps adding to some of her favorite stocks.

Mentions: AMD SHOP

News Image
24 days ago - Yahoo Finance

Why Viking Therapeutics Stock Popped Again Today

Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.

Mentions: LLY VKTX REGN SNY ...

News Image
24 days ago - Zacks Investment Research

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News Image
a month ago - Shareholders Foundation, Inc.

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

/PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA)....

News Image
a month ago - Investor's Business Daily

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Mentions: SIRI RY RY.CA SRPT ...

News Image
a month ago - Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:...

News Image
a month ago - DJS Law Group LLP

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

/PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Intellia Therapeutics ("Intellia" or "the Company") (NASDAQ: NTLA) for...